MaxCyte, Inc. Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount
MaxCyte, Inc. (MXCT) reported Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount of $1.07 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-11.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate · last filed 2025-03-11
- MaxCyte, Inc. effective income tax rate reconciliation, change in enacted tax rate, amount for fiscal 2024 was $1.07M.
- MaxCyte, Inc. effective income tax rate reconciliation, change in enacted tax rate, amount for fiscal 2023 was -$819.00K, a 125.28% decline from fiscal 2022.
- MaxCyte, Inc. effective income tax rate reconciliation, change in enacted tax rate, amount for fiscal 2022 was $3.24M, a 26.28% increase from fiscal 2021.
- MaxCyte, Inc. effective income tax rate reconciliation, change in enacted tax rate, amount for fiscal 2021 was $2.57M, a 580.40% increase from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount 12 month | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount 12 month as first filed |
|---|---|---|
| 2024-12-31 | $1.07M 10-K · filed 2025-03-11 | |
| 2023-12-31 | -$819.00K 10-K · filed 2025-03-11 | |
| 2022-12-31 | $3.24M 10-K · filed 2024-03-12 | $3.24M 10-K · filed 2023-03-15 |
| 2021-12-31 | $2.57M 10-K · filed 2023-03-15 | |
| 2020-12-31 | $377.10K 10-K · filed 2022-03-22 | |
| 2019-12-31 | -$29.70K 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |